Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases | Cardiology/Vascular Diseases | Hepatology (Liver, Pancreatic, Gall Bladder) | Genetic Disease
Clinical Trials: Cystic Fibrosis
A listing of clinical trials currently looking for volunteers to enroll in Cystic Fibrosis studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : UAB/CHS Cystic Fibrosis Center
I Change Adherence & Raise Expectations
Birmingham : Site Ref # / Investigator 78920
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Birmingham :
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Birmingham :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Birmingham : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Alaska
Anchorage : Site Ref # / Investigator 79256
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Arizona
Phoenix : Phoenix Children's Hospital
I Change Adherence & Raise Expectations
Arkansas
Little Rock : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
California
Los Angeles : University of Southern California
Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
Oakland : Kaiser Permanente Medical Care Program
I Change Adherence & Raise Expectations
Oakland : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Orange : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Palo Alto :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Colorado
Denver : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Denver :
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
Connecticut
Hartford : Connecticut Children's Medical Center
I Change Adherence & Raise Expectations
Hartford :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Florida
Altamonte Springs : Central Florida Pulmonary Group
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Gainesville : Site Ref # / Investigator 78928
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Jacksonville : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Jacksonville : Site Ref # / Investigator 78898
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Orlando : Site Ref # / Investigator 78917
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
View More »
Tampa :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Georgia
Atlanta : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Atlanta : Emory University
Prevention of Cystic Fibrosis Diabetes
Atlanta : Children's Healthcare of Atlanta at Scottish Rite
Prevention of Cystic Fibrosis Diabetes
Atlanta :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Idaho
Boise : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Illinois
Chicago : Children's Memorial Hospital
I Change Adherence & Raise Expectations
Chicago :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Chicago :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Chicago : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Indiana
Indianapolis : Riley Hospital for Children
I Change Adherence & Raise Expectations
Indianapolis : Site Ref # / Investigator 78903
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Indianapolis : Riley Hospital for Children
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Iowa
Iowa City :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Kansas
Kansas City : University of Kansas Medical Center
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Kentucky
Lexington :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Maine
Portland : Maine Medical Center
I Change Adherence & Raise Expectations
Maryland
Baltimore : Johns Hopkins University
Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis
Baltimore :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Massachusetts
Boston : Children's Hospital Boston
I Change Adherence & Raise Expectations
Boston : Boston Children's Hospital
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Boston : Children's Hosptital, Boston
Structure and Function of Salivary Proteins
Boston :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Boston :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
View More »
Boston : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Michigan
Ann Arbor : University of Michigan Health System
I Change Adherence & Raise Expectations
Ann Arbor :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Detroit :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Grand Rapids :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Grand Rapids : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Minnesota
Minneapolis : University of Minnesota
A Study of Sweat Testing Using a Quantitative Patch
Minneapolis : Site Ref # / Investigator 79253
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Minneapolis : University of Minnesota - Cystic Fibrosis Center
Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
Minneapolis :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Missouri
Kansas City : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
St. Louis : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
St. Louis :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Nebraska
Omaha : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Omaha :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Nevada
Las Vegas : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Las Vegas : Children's Lung Specialists
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
New Hampshire
Manchester : Site Ref # / Investigator 78957
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
New Jersey
Morristown : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
New Mexico
Albuquerque : UNM Clinical and Translational Center
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
New York
Great Neck : Biomedical Research Alliance of New York
Cystic Fibrosis - Pediatric
New Hyde Park : Biomedical Research Alliance of New York
Cystic Fibrosis
View More »
Buffalo : Women and Children's Hospital of Buffalo
I Change Adherence & Raise Expectations
New Hyde Park : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
New York :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Rochester : University of Rochester Medical Center
I Change Adherence & Raise Expectations
Syracuse : Site Ref # / Investigator 78912
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Syracuse : SUNY Upstate University
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Syracuse :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Valhalla :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
North Carolina
Chapel Hill : UNC-Chapel Hill
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Chapel Hill : UNC Hospitals
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
Chapel Hill :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Chapel Hill : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Durham : Duke University Medical Center
I Change Adherence & Raise Expectations
View More »
Durham : Duke University Medical Center
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
North Dakota
Bismarck : St. Alexius Medical Center
A study for cystic fibrosis patients who might have a condition called Fibrosing Colonopathy (FC).
Ohio
Akron : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Akron : Akron Children's Hospital
I Change Adherence & Raise Expectations
Cincinnati : UC Health - University of Cincinnati
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Cincinnati : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Cleveland : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
View More »
Cleveland : Rainbow Babies and Children's Hospital
I Change Adherence & Raise Expectations
Columbus : Nationwide Children's Hospital
I Change Adherence & Raise Expectations
Columbus : Nationwide Children's Hospital, Ohio State University
Prevention of Cystic Fibrosis Diabetes
Columbus : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Columbus : Nationwide Children's Hospital
Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
Toledo : Toledo Children's Hospital
I Change Adherence & Raise Expectations
Oklahoma
Oklahoma City : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Oklahoma City : Santiago Reyes, MD
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Oklahoma City : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Pennsylvania
Hershey : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Philadelphia :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Philadelphia :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Pittsburgh :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Pittsburgh :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
View More »
Pittsburgh : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
South Carolina
Charleston : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Charleston :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Charleston : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Columbia : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Tennessee
Nashville :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Texas
Dallas : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Dallas :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Fort Worth : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Fort Worth :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Houston : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
View More »
Houston :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Houston :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
San Antonio : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Utah
Salt Kale City : Primary Children's Medical Center
I Change Adherence & Raise Expectations
Salt Lake City : University of Utah
A Study of Sweat Testing Using a Quantitative Patch
Salt Lake City :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Salt Lake City : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Vermont
Colchester : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Virginia
Richmond :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Washington
Seattle : Seattle Children's Hospital
I Change Adherence & Raise Expectations
Seattle :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Seattle : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Tacoma : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
West Virginia
Morgantown : West Virginia University
I Change Adherence & Raise Expectations
Morgantown :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Wisconsin
Madison : American Family Children's Hospital
A Study of Sweat Testing Using a Quantitative Patch
Madison : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Madison :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Milwaukee : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Argentina
Buenos Aires : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Capital Federal : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Córdoba : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Paraná Entre Ríos : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Australia
Clayton : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
New Lambton Heights : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Victoria : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Belgium
Antwerp : University Hospital Antwerp - Universitair Ziekenhuis Antwerpen (UZA)
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Leuven :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Bulgaria
Pleven : Clinic of Paediatric Diseases at UMHAT Dr Georgi Stranski
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Plovdiv : Clinic of Genetic and Paediatric Diseases at UMHAT Sveti Georgi
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Ruse : Specialized Hospital for Active Treatment of Pulmological and Phtisiatric Disease
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Varna : Multiprofile Clinic for Specialized Pediatric Clinic at MHAT Sveta Marina
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Canada
Calgary : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Halifax : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Montreal : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Montreal : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Toronto : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
View More »
Winnipeg : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
France
Bron : Centre de ressources et de compétences pour la mucovisidose, enfants
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
Giens Cedex : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Lyon : Centre de Ressource et de Compétence Mucoviscidose Pédiatrique Centre de Référence Mucoviscidose
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis
Lyon :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Montpellier : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
View More »
Montpellier :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Paris : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Paris :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation
Reims : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Roscoff : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Germany
Berlin : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Bochum : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Bochum : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Dresden : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Erlangen : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
View More »
Essen : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Essen : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Frankfurt : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Frankfurt : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Frankfurt : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Hannover : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Jena : Jena University Hospital, Universitaetsklinikum Jena
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Jena : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Koeln : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Koeln : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Koln : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
München : Klinikum der Universitat Munchen Medizinische Klinik-Innenstadt
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Munich : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Tubingen : University Children's Clinic Tubingen
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Greece
Patras : Novartis Investigative site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Thessaloniki : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Hungary
Budapest : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Debrecen : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Kaposvar : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Szeged : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Italy
Firenze : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Genova : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Messina : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Napoli : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Palermo : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
View More »
Roma : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Verona : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Japan
Kagawa : Site Reference ID/Investigator# 65530 Updated
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Kagoshima : Site Reference ID/Investigator# 65527 Updated
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Kanazawa : Site Reference ID/Investigator# 65529 Updated
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Nagoya : Site Reference ID/Investigator# 73813 Updated
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Sendai : Site Reference ID/Investigator# 65528 Updated
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
View More »
Tokyo : Site Reference ID/Investigator# 67122 Updated
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Tsukuba : Site Reference ID/Investigator# 88673 Updated
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Mexico
Mexico : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Monterrey : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Poland
Gdansk : Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem Poradnia Leczenia Mukowiscydozy
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Gdansk : Specjalistyczny Zespot Opieki Zdrowotnej nad Matka i Dzieckiem Poradnia Leczenia Mukowiscydozy
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Karpacz : Centrum Pulmonologii i Alergologii w Karpaczu
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Lodzi : Wojewodzki Szpital Specjalistyczny im Kopernika
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Lublin : Dziecięcy Szpital Kliniczny im. Prof. Antoniego Gębali
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
View More »
Lublin : ALERGOTEST s.c Specjalistyczne Centrum Medyczne
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Poznan : Szpital Kliniczny im Karola Jonschera
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Poznan : Szpital Kliniczny im Karola Jonschera
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Rabka Zdrój : NZOZ Sanatorium Cassia Villa Medica
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Rabka Zdrój : NZOZ Sanatorium Cassia Villa Medica
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Rzeszow : NZOZ Podkarpacki Osrodek Pulmonologii i Alergologii
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Rzeszow : NZOZ Podkarpacki Osrodek Pulmonologii i Alergologii
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Warszawa : IRMED Irena Wojciechowska
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Warszawa : Centrum Zdrowia Matki, Dziecka i Mlodziezy
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Qatar
Doha : Hamad Medical Corporation
Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)
Russian Federation
Barnaul : Site Reference ID/Investigator# 80716 Updated
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
Kazan : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Moscow : Site Reference ID/Investigator# 80693 Updated
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
Moscow : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Novosibirsk : Site Reference ID/Investigator# 80698 Updated
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
View More »
Novosibirsk : Site Reference ID/Investigator# 80713 Updated
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
Orenburg : Site Reference ID/Investigator# 80715 Updated
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
Voronezh : Site Reference ID/Investigator# 80697 Updated
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
Voronezh : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Yaroslavl : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Spain
Barcelona : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Sabadell : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Valencia : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Switzerland
Lausanne : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Zurich : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
United Kingdom
Belfast : Celerion
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
Belfast :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Cambridge : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Edinburgh :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Liverpool : Liverpool Heart & Chest Hospital
A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis
View More »
Liverpool : Liverpool Heart and Chest Hospital
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
London : Royal Brompton Hospital, Department of Respiratory Medicine
Extension Study of Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infection
Sheffield : Sheffield Children's Hospital, The Academic Unit of Child Health
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.